ReviewF1000Research2020
Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease.
Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 68 citations in OpenAlex.
- Prediction Model of Postoperative Severe Hypocalcemia in Patients with Secondary Hyperparathyroidism Based on Logistic Regression and XGBoost Algorithm.Computational and mathematical methods in medicine · 2022Trial
- Development of a nomogram for predicting severe post-parathyroidectomy hypocalcemia in patients with secondary hyperparathyroidism: a retrospective cohort study.Gland surgery · 2026Article
- Pre-Parathyroidectomy PTH as an Integrated Biomarker of Glandular Remodeling and Skeletal Turnover in Secondary Hyperparathyroidism.International journal of molecular sciences · 2026Review
- Article
- The impact of psychosocial factors on secondary hyperparathyroidism and vitamin D deficiency in adults with congenital heart disease-the CHD-HYPER study.Frontiers in nutrition · 2026Article
- Combination therapy with nutritional vitamin D and calcimimetics in secondary hyperparathyroidism: a mechanism-based approach to restoring PTH regulation.Frontiers in nutrition · 2026Review
- Investigation of secondary hyperparathyroidism and its contributing factors in hemodialysis patients: A cross-sectional study.Journal of education and health promotion · 2026Article
- A patient with CKD complicated by secondary hyperparathyroidism and parathyroid carcinoma: a case report.Frontiers in medicine · 2026Article
- Association between elevated serum parathyroid hormone and QTc interval prolongation in chronic kidney disease patients.International urology and nephrology · 2025Article
- Postoperative serum changes in calcium, phosphorus, iPTH, CRP, IL-6, and TNF-p levels in patients with secondary hyperparathyroidism.Journal of medical biochemistry · 2025Article
- Paradoxical effects of parathyroidectomy and sodium thiosulfate in a hemodialysis patient with calciphylaxis: a case report of persistent metastatic calcification.Frontiers in medicine · 2025Article
- Beyond secondary hyperparathyroidism: Diagnosing primary parathyroid abnormalities in a patient with chronic kidney disease.Radiology case reports · 2024Article
- Changes in cardiac functions in patients treated with parathyroidectomy for secondary hyperparathyroidism.Updates in surgery · 2024Article
- Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH.The Journal of clinical endocrinology and metabolism · 2024 · on this mapArticle
- COVID-19-Induced Refractory Symptomatic Hypocalcemia in a Patient With Parathyroid Gland Reimplantation.Case reports in endocrinology · 2024Article
- Real-world usage of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices.Clinical kidney journal · 2024Article
- Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects.Drug design, development and therapy · 2024Article
- Complications after radiofrequency ablation of hyperparathyroidism secondary to chronic kidney disease.Renal failure · 2023Article
- Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse effects on 1,25-dihydroxyvitamin D and PTH.medRxiv : the preprint server for health sciences · 2023Article
- [MiR-301a-5p modulates parathyroid hormone secretion in secondary hyperparathyroidism possibly by regulating calcium-sensing receptor].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary hyperparathyroidism is a complex pathology that develops as chronic kidney disease progresses. The retention of phosphorus and the reductions in calcium and vitamin D levels stimulate the synthesis and secretion of parathyroid hormone as well as the proliferation rate of parathyroid cells. Parathyroid growth is initially diffuse but it becomes nodular as the disease progresses, making the gland less susceptible to be inhibited. Although the mechanisms underlying the pathophysiology of secondary hyperparathyroidism are well known, new evidence has shed light on unknown aspects of the deregulation of parathyroid function. Secondary hyperparathyroidism is an important feature of chronic kidney disease-mineral and bone disorder and plays an important role in the development of bone disease and vascular calcification. Thus, part of the management of chronic kidney disease relies on maintaining acceptable levels of mineral metabolism parameters in an attempt to slow down or prevent the development of secondary hyperparathyroidism. Here, we will also review the latest evidence regarding several aspects of the clinical and surgical management of secondary hyperparathyroidism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.